약물 재창출용 인공지능(AI) 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 구성 요소, 용도, 프로세스, 최종 사용자, 솔루션

The global AI for Drug Repurposing Market is projected to grow from $1.3 billion in 2025 to $7.1 billion by 2035, at a compound annual growth rate (CAGR) of 18.4%. The AI for Drug Repurposing Market continues to expand alongside increasing pharmaceutical investment in artificial intelligence and computational biology. According to official data from the National Institutes of Health (NIH), thousands of drug repurposing-related clinical studies are registered globally, reflecting growing research activity. The U.S. Food and Drug Administration (FDA) continues to approve therapies developed through supplemental indications, reinforcing commercial interest in repurposing strategies. Global AI investment in healthcare has accelerated as pharmaceutical companies increasingly deploy machine learning to shorten discovery timelines, improve candidate prioritization, and reduce research costs, supporting double-digit market growth expectations over the coming decade.

The services segment plays a critical role in enabling organizations to deploy and optimize AI-driven drug repurposing solutions across pharmaceutical and biotechnology workflows. Consulting services focus on AI strategy, regulatory planning, and workflow optimization, while integration services connect AI platforms with laboratory information management systems, clinical databases, and genomic repositories. Maintenance services ensure continuous software updates, cybersecurity, and system performance, whereas training and support improve workforce proficiency in AI model interpretation and data management. Growing adoption of cloud-based analytics, increasing outsourcing of AI implementation, and expanding demand for customized bioinformatics solutions are expected to sustain strong service revenues throughout the forecast period.

The solutions segment encompasses AI platforms that improve different stages of pharmaceutical innovation through predictive analytics and computational modeling. Drug discovery solutions identify novel biological targets and screen molecular libraries efficiently, while drug development solutions optimize preclinical validation, biomarker identification, and clinical trial design. Drug repositioning solutions leverage genomic, proteomic, and clinical datasets to identify alternative therapeutic indications for approved or investigational drugs. These solutions reduce research timelines, improve decision accuracy, and lower development risks. Continuous advancements in deep learning algorithms, multimodal data integration, and explainable AI are expected to strengthen solution adoption across pharmaceutical research ecosystems.

Geographical Overview

North America maintains a leading position in the AI for Drug Repurposing Market due to its advanced pharmaceutical ecosystem, extensive biomedical research infrastructure, and widespread adoption of artificial intelligence technologies. The presence of major pharmaceutical manufacturers, biotechnology innovators, cloud computing providers, and academic research institutions creates a collaborative innovation environment. Strong funding from public health agencies, well-established clinical trial networks, and favorable intellectual property protection encourage rapid commercialization of AI-enabled drug repurposing platforms. Continuous investments in precision medicine, genomic research, and digital health initiatives further strengthen regional competitiveness and sustain long-term market expansion.

Asia-Pacific demonstrates substantial market potential through expanding pharmaceutical manufacturing capabilities, increasing AI research investments, and growing digital healthcare infrastructure. Countries including China, Japan, South Korea, India, and Singapore are strengthening national AI strategies while supporting biotechnology innovation through public-private partnerships and research funding. Rising healthcare expenditure, increasing availability of biomedical datasets, and growing collaborations between technology companies and pharmaceutical organizations are accelerating solution deployment. Expansion of clinical research activities, supportive government initiatives, and improvements in cloud computing infrastructure are expected to reinforce regional demand for AI-driven drug repurposing platforms over the forecast period.

Key Trends and Drivers

Integration of AI with Big Data Analytics:

The AI for drug repurposing market is increasingly leveraging big data analytics to enhance the accuracy and efficiency of drug discovery processes. By integrating AI with vast datasets from clinical trials, genomic studies, and patient records, companies can identify potential drug candidates more quickly and accurately. This trend is driven by the need to reduce the time and cost associated with traditional drug development, as well as the growing availability of healthcare data.

AI Accelerates Faster and Cost-Efficient Drug Repurposing:

Growing pressure to reduce pharmaceutical research costs and accelerate time-to-market is the primary driver of the AI for Drug Repurposing Market. Conventional drug development remains expensive and time-intensive, prompting organizations to leverage AI for identifying new indications for existing compounds with established safety profiles. The availability of large biomedical datasets, expanding computational capabilities, and increased collaborations between pharmaceutical companies, AI developers, and research institutions continue to strengthen market adoption and investment.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Component
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Machine Learning
  • 4.1.2 Deep Learning
  • 4.1.3 Natural Language Processing
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Software
  • 4.2.2 Platform
  • 4.2.3 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting
  • 4.3.2 Implementation
  • 4.3.3 Support and Maintenance
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Cloud-based
  • 4.4.2 On-premise
  • 4.4.3 Hybrid
  • 4.4.4 Others
• 4.5 Market Size & Forecast by Component (2020-2035)
  • 4.5.1 AI Algorithms
  • 4.5.2 Data Management Tools
  • 4.5.3 Analytics
  • 4.5.4 Others
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Oncology
  • 4.6.2 Cardiology
  • 4.6.3 Neurology
  • 4.6.4 Infectious Diseases
  • 4.6.5 Rare Diseases
  • 4.6.6 Others
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Pharmaceutical Companies
  • 4.7.2 Biotechnology Companies
  • 4.7.3 Research Institutes
  • 4.7.4 Contract Research Organizations
  • 4.7.5 Others
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Target Identification
  • 4.8.2 Drug Screening
  • 4.8.3 Clinical Trials
  • 4.8.4 Post-market Surveillance
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Drug Discovery
  • 4.9.2 Drug Development
  • 4.9.3 Drug Repositioning
  • 4.9.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Component
    • 5.2.1.6 Application
    • 5.2.1.7 End User
    • 5.2.1.8 Process
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Component
    • 5.2.2.6 Application
    • 5.2.2.7 End User
    • 5.2.2.8 Process
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Component
    • 5.2.3.6 Application
    • 5.2.3.7 End User
    • 5.2.3.8 Process
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Component
    • 5.3.1.6 Application
    • 5.3.1.7 End User
    • 5.3.1.8 Process
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Component
    • 5.3.2.6 Application
    • 5.3.2.7 End User
    • 5.3.2.8 Process
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Component
    • 5.3.3.6 Application
    • 5.3.3.7 End User
    • 5.3.3.8 Process
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Component
    • 5.4.1.6 Application
    • 5.4.1.7 End User
    • 5.4.1.8 Process
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Component
    • 5.4.2.6 Application
    • 5.4.2.7 End User
    • 5.4.2.8 Process
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Component
    • 5.4.3.6 Application
    • 5.4.3.7 End User
    • 5.4.3.8 Process
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Component
    • 5.4.4.6 Application
    • 5.4.4.7 End User
    • 5.4.4.8 Process
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Component
    • 5.4.5.6 Application
    • 5.4.5.7 End User
    • 5.4.5.8 Process
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Component
    • 5.4.6.6 Application
    • 5.4.6.7 End User
    • 5.4.6.8 Process
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Component
    • 5.4.7.6 Application
    • 5.4.7.7 End User
    • 5.4.7.8 Process
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Component
    • 5.5.1.6 Application
    • 5.5.1.7 End User
    • 5.5.1.8 Process
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Component
    • 5.5.2.6 Application
    • 5.5.2.7 End User
    • 5.5.2.8 Process
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Component
    • 5.5.3.6 Application
    • 5.5.3.7 End User
    • 5.5.3.8 Process
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Component
    • 5.5.4.6 Application
    • 5.5.4.7 End User
    • 5.5.4.8 Process
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Component
    • 5.5.5.6 Application
    • 5.5.5.7 End User
    • 5.5.5.8 Process
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Component
    • 5.5.6.6 Application
    • 5.5.6.7 End User
    • 5.5.6.8 Process
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Component
    • 5.6.1.6 Application
    • 5.6.1.7 End User
    • 5.6.1.8 Process
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Component
    • 5.6.2.6 Application
    • 5.6.2.7 End User
    • 5.6.2.8 Process
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Component
    • 5.6.3.6 Application
    • 5.6.3.7 End User
    • 5.6.3.8 Process
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Component
    • 5.6.4.6 Application
    • 5.6.4.7 End User
    • 5.6.4.8 Process
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Component
    • 5.6.5.6 Application
    • 5.6.5.7 End User
    • 5.6.5.8 Process
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Insilico Medicine
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Atomwise
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 BenevolentAI
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Exscientia
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Recursion Pharmaceuticals
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Cyclica
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Healx
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 BioXcel Therapeutics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 GNS Healthcare
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 NuMedii
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Pharnext
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Insitro
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Deep Genomics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Cloud Pharmaceuticals
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Standigm
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 AI Therapeutics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 XtalPi
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 BERG Health
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 PathAI
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 A2A Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us